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Background: Longstanding complex regional pain syndrome (CRPS) is refractory to treatment with established analgesic
drugs in most cases, and for many patients, alternative pain treatment approaches, such as with neuromodulation
devices or rehabilitation methods, also do not work. The development of novel, effective treatment technologies is,
therefore, important. There are preliminary data suggesting that low-dose immunoglobulin treatment may significantly
reduce pain from longstanding CRPS.
Methods/Design: LIPS is a multicentre (United Kingdom), double-blind, randomised parallel group, placebo-controlled
trial, designed to evaluate the efficacy, safety, and tolerability of intravenous immunoglobulin (IVIg) 0.5 g/kg plus
standard treatment, versus matched placebo plus standard treatment in 108 patients with longstanding complex
regional pain syndrome. Participants with moderate or severe CRPS of between 1 and 5 years duration will be randomly
allocated to receive IVIg 0.5 g/kg (IntratectTM 50 g/l solution for infusion) or matching placebo administered day 1 and
day 22 after randomisation, followed by two optional doses of open-label medication on day 43 after randomisation
and on day 64 after randomisation. The primary outcome is the patients’ pain intensity in the IVIG group compared
with the placebo group, between 6 and 42 days after randomisation. The primary trial objective is to confirm the
efficacy and confidently determine the effect size of the IVIG treatment technology in this group of patients.
Trial registration: ISRCTN42179756 (Registered 28 June 13).
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Complex regional pain syndrome (CRPS) is a post-
traumatic pain in a limb, associated with sensory, motor,
autonomic, skin and bone changes [1,2]. CRPS can resolve
spontaneously, but if a spontaneous resolution does not
occur early, it is less likely to occur later. Many patients
with CRPS have no effective method to relieve their on-
going pain [3]. Those patients with CRPS of moderate to
severe pain intensity, the target group for this study, report
on average a very poor quality of life, and they usually can-
not work [4]. Immunoglobulin treatment for chronic pain
is a novel technology [5]. In one of the first open trials, we
found that low dose intravenous immunoglobulin (IVIg)* Correspondence: andreas.goebel@liv.ac.uk
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unless otherwise stated.may be effective in some patients with CRPS (for 11 par-
ticipants: three had >70% pain relief, two had >25% but <
70%, and six had 0 to 25%, following a variable number of
low-dose infusion repeats) [6]. We later showed that in
one patient repeat treatments provided reproducible ef-
fects [7]. Recently, we confirmed in a UK single-centre
crossover, randomised, placebo-controlled trial (RCT) [8],
that a single, low dose (0.5 g/kg) infusion of IVIg signifi-
cantly reduced pain in patients with CRPS (n = 13, pain in-
tensity on a validated 11-point numeric rating scale (NRS)
higher than 4 (NRS 0 = no pain, 10 = pain as bad as you
can imagine [9]); these patients had a disease duration of
0.5 to 2.5 years. The treatment difference was 1.55 NRS
points (95% CI: 1.29 to1.82, P <0.001). In a responder ana-
lysis (12 patients had received treatment), three patients
had ≥50% less pain (4.5, 5 and 5 NRS points) after IVIgLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients had 2 and 2.5 NRS points less pain (29% and 31%
less pain). One patient had 2 NRS points less pain (25%
less pain) after saline compared with after IVIg treatment.
The average effect duration was 5 weeks. There was also a
significant overall reduction of CRPS-related, non-painful
symptoms and, in responders, improved sleep and global
improvement, with few adverse events (headaches and
pain increases for <3 days). Post-infusion questionnaires
showed successful blinding of patients and study doctors.
Recently we commenced a trial to explore whether sub-
cutaneous immunoglobulin, in weekly self-administration
at home over one year, would provide sustained pain relief
in initial responders to 0.5 g/kg IVIg (ISRCTN63226217).
We invited all five patients who experienced at least 2 NRS
points less pain after IVIg in the earlier RCT. Of these pa-
tients, one declined participation, and a second patient un-
fortunately developed metastasizing colon cancer. Three
patients participated. By August 2011, two patients, with
disease durations of 6 and 5 years at study entry and base-
line pain intensities of NRS 7 and 6 had experienced sus-
tained pain reduction of >70% for 12 and 3.5 months,
respectively. The third patient, who had had 31% relief in
the RCT, showed no benefit. The two responding patients
reported major improvement in their quality of life. EQ5D
scores [10] improved from 0.26 and 0.30 at baseline to 0.66
and 0.65 at twelve and three months and reduced interfer-
ence of their pain with daily functioning; Brief Pain Inven-
tory [11] interference scores (pain interference = the impact
of pain on activities of daily life) improved from 7.7 and 6.1
at baseline to 1.4 and 0 at twelve and three months.
The implication of the existing research for this trial is
that the above evidence provides proof of concept for
the efficacy of low-dose immunoglobulin treatment for
patients with CRPS of moderate to severe pain intensity
(msCRPS) in reducing pain, with an advantageous side-
effect profile. These data also suggest that this treatment
may improve quality of life and pain interference. Be-
cause the numbers of treated patients have been small,
and most research was conducted in a single centre, it is
now important to confirm these findings in a larger
group of patients and across several centres, to gain con-
fidence about both efficacy and affect size of this novel
technology, and to demonstrate its generalizability.
The primary objective of this trial is to gain, within
44 months, both definite proof of the clinical efficacy
and a more confident estimate of the effect size of low-
dose IVIg treatment to reduce pain in patients with
moderate or severe complex regional pain syndrome.
Secondary objectives are to achieve a better under-
standing of this technology including the following:
1. stability of effect with repeat administration;
2. factors predicting a beneficial response;3. effects on additional outcome parameters including
stimulus evoked pain, pain interference, quality of
life, and short-term risk profile;
4. health economics evaluation; and
5. creation of a bank of biological samples for future
complex regional pain syndrome research.
The primary outcome will be the average 24-h pain in-
tensity over 37 days (to be completed on day 6 to day 42
after randomisation to record pain intensity during the
previous 24 hours).
The number of study sites will be seven: all UK-based
specialist pain clinics in secondary care (Liverpool,
London, Bath, Glasgow, Norfolk and Norwich, Cambridge,
Leicester).
The study population size will be 108 (54 in each study
arm).
The study duration will be 44 months (from study set-
up to analysis).
Methods/Design
LIPS is a multicentre, randomised, double-blind, placebo-
controlled, parallel group trial with an open extension.
The parallel group design is an established research tech-
nique; the open extension is an optional trial element,
where patients who have completed the parallel, blinded
phase can request to receive one, or maximally two doses
of IVIG ‘openly’, that is, assured that what they receive is
IVIG (there is no placebo control). This extension is in-
cluded to take account of service users’ preferences.
Blinding will be achieved by preparing both study drug
and placebo (0.1% albumin in normal saline) solution
into identical bottles. The albumin is added to achieve
indistinguishable foaming and colour to the IVIg. Batch
numbers and expiry dates for both the active and pla-
cebo drug will be indistinguishable.
For the time frame, study day 0 is defined as the day
of randomisation, and a screening visit is scheduled
maximally three weeks prior (day −21); patients then re-
ceive blinded infusions on days 1 and 22. Thereafter, in
those who decide to receive open infusion on day 43
and day 64, pain diaries will be completed daily from
day 43 to day 85 and then weekly for 9 weeks further to
explore the duration of combined drug- and unspecific
treatment effects (Additional file 1).
The sample size is 108 patients (54 patients per study
arm). An interim analysis will be performed for futility
and safety after half of patients have completed the trial. It
will be suggested that the trial be stopped if there is a sta-
tistically significant difference between the groups in the
‘wrong’ direction at the 5% level (that is, one-sided test at
the 2.5% level). This stopping rule will have a negligible ef-
fect on the type I error and power of the trial. There will
no statistical stopping rule for efficacy although the DMC
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there is an overwhelming positive effect of IVIg.
Clinical stopping rules will relate to unexpectedly poor
recruitment and excessive withdrawals.
Primary outcome measure
The primary outcome is the average 24-h pain intensity
over 37 days, recorded in pain diary entries for the pre-
vious 24 hours and collected on days 6 to 42 (day 1 =
day of first infusion). Consenting patients, who provide a
mobile phone number, will be prompted automatically
by SMS daily from day 2 to 42 to enter their pain inten-
sity into their diary. In addition, return SMSs from the
patient, with the daily NRS pain value, will be automatic-
ally saved as backup for the paper diary. The paper diary
score will override the texted diary score; however, every
effort will be made to resolve any discrepancies. In par-
ticipating patients, an unexplained lack of a response
over two or three days will prompt a phone call from
the study nurse to confirm that there are no issues.
Secondary and exploratory outcome measures
1. Secondary outcomes will be pain interference
measured using the interference subscale of the Brief
Pain Inventory [11], and quality of life measured
using the Euroqol EQ-5D-5 L [12].
2. All other outcomes are exploratory
3. List of measures to be used (measurement times see
Additional file 1)
4. Detailed daily - (three items: pain unpleasantness
[13], average 24-h NRS pain intensity, last 24-h sleep
quality [14]), and simplified weekly (weekly NRS
pain intensity) pain diaries
5. Adverse events
6. Brief Pain Inventory- (diagram, worst pain intensity,




10. Skin temperature measured with a surface
thermometer
11. Limb volume measured with a water-bath technique
12. EQ-5D (5 Item) [12]
13. Expectations from treatment [15]
14. Functional items and fatigue suggested by and
developed together with patient group (5 scales)
15. Patient Global Impression of change [16]
16. Hospital Anxiety and Depression Scale [17]
17. Health and social care utilisation
18. Limb exam recording Budapest CRPS signs, and
any additional abnormalities on inspection, and
sensory (cotton wool, pinprick, cold-fork) and
motor (observation of active range) examination19. McGill [18]
20. Quantitative Sensory Testing in 40 patients with
stimulus-evoked pain, excepting thermosensitivities
(only in three trial centres)
21. Sullivan’s Pain Catastrophising Scale [19]
22. Work interference (Stanford Presenteeism Scale) [20]
23. Neglect-like symptoms in CRPS [21]
Definition of end of study
The end of the study will be the last participant’s final
study contact at day 148 (for those who elect to receive
open label infusions) or at day 64 (for those who elect
not to receive open label infusion).
SAEs will be monitored for 21 days after final dose of
IVIg or until resolution.
Subject population
Inclusion criteria
1. Diagnosis of Complex Regional Pain Syndrome I or
II according to Budapest research criteria
(Additional file 2) [22]
2. Disease duration of 1 to 5 years and a mean pain
intensity on an 11-point (0 to 10) Numeric Rating
Scale (NRS) over the first seven daily entries after
screening within a pre-defined range (see section 9
for details of pain thresholds for eligibility)
3. Failure to respond (poor efficacy or unacceptable
side effects) to drugs recommended for the
treatment of neuropathic pain [23], including
pregabalin or gabapentin, tricyclic antidepressants,
and mild and strong opioids (where not
contraindicated or refused by the patient).
4. Previous specialised pain physiotherapy [24] (where
not contraindicated or refused by the patient)
5. Willingness to confirm the use of adequate birth
control while on the trial will be required in
premenopausal women without evidence for an
inability to become pregnant.
6. Willingness to not start any other treatment for
CRPS during the parallel part of the trial
7. Age 18 years and above
Exclusion criteria
Any individuals meeting any of the following will be
excluded from the study:
1. Other significant chronic pains, which in the view of
the study doctor may make assessment of the pain
arising from CRPS difficult.
2. If the patient recently started a new therapy for
CRPS that, in the view of the study doctor, may
change the patient’s pain level during the time of
participation in the trial.
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4. Litigation. Patients in litigation will be excluded only
if conclusion of that litigation is imminent during
the course of the study.
5. If patient is pregnant or breastfeeding.
6. Complete IgA deficiency.
7. Rare contraindications to IVIg therapy as per
summary of product characteristics (SmPC).
8. Receiving IVIg for other reasons.
9. Patient was previously enrolled in CRPS IVIg/SCIG
trials.
10. Ongoing drug or alcohol abuse.
11. Psychiatric or mental health disorder that could, in
the judgement of the site investigator, interfere with
successful study participation.
12. Unwillingness or inability to complete daily diaries
or an inability to understand the questionnaires
being used.
13. Cancer other than basal cell carcinoma within the
last 5 years. However, those patients who have
received definitive treatment, such as curative
surgery more than 6 months ago, with no known
recurrence can be included.
14. A history of hypercoagulable or thrombophilic
clotting abnormalities.
15. A history of thrombembolic events: ischaemic
stroke, confirmed myocardial infarction, pulmonary
embolism; deep venous thrombosis except where
immobility related (for example, after injury or
operation).
16. Unstable angina.
17. Renal failure or serum creatinine greater than 1.5
times the upper limit of normal at screening.
18. Any medical condition that, in the opinion of the
investigator, would make it unsafe for the patient to
participate or which would interfere with
assessment of the outcome measures.
19. Participation in another interventional trial within
3 months of randomisation. Participation in non-
interventional studies is not a reason for exclusion.
Screening, recruitment and consent
Patients will be identified through clinics at each of the
seven centres, which are all specialist pain/complex re-
gional pain syndrome clinics in secondary care. Strategies
will be implemented to maximise awareness of the trial in
the patient population and increase referrals to the recruit-
ing centres (see details of strategies to be employed in
Additional file 3). Patients will be given the patient infor-
mation sheet to read at least 24 hours before the screening
visit, where they will give informed consent. At the screen-
ing visit, there will be an opportunity for the partici-
pants to ask questions of a member of staff trained in all
trial procedures, as delegated by the PI. The PrincipalInvestigator or a co-investigator at each site will ensure
that the participants meet the inclusion and exclusion cri-
teria at the point of screening.
Patients will be telephoned at least 8 days, and max-
imally 14 days, after screening to check pain diary scores
and confirm eligibility to participate.
Visit 2 will be scheduled no earlier than 10 days, and
no later than three weeks, after visit 1.
Screen failures may be rescreened ONLY where there
is a short-term reason for ineligibility, such as non-
availability for study visits due to planned holidays or an
ongoing acute illness. Pain diary scores that make the
patient ineligible cannot be considered a reason for
rescreening.
A screening log will be kept at site to document details of
patients invited to be screened for participation in the
study. For patients who decline or are ineligible, this will
document any reasons available for nonparticipation (where
provided). The log will ensure potential participants are
only approached once.
The original signed consent form will be retained in
the investigator site file, with a copy in the participant’s
hospital medical notes, and a copy provided to the par-
ticipant. The participant will specifically consent to their
GP being informed of their participation in the study.




Matching placebo infusions will be manufactured for the
5 g/100 ml and 10 g/200 ml IntratectTM IVIg infusion.
These will be identical in appearance to the active infu-
sions - they will be indistinguishable by colour and foam-
ing of the infusion.
IntratectTM IVIg infusion
The experimental intervention is 0.5 g/kg IntratectTM
IVIg infusion, in combination with ongoing normal stand-
ard treatment for complex regional pain syndrome.
For reported side effects of IntratectTM IVIg infusion,
please refer to section 17.2 and the summary of product
characteristics (Additional file 4).
Contraindications include
hypersensitivity to any of the components and
hypersensitivity to homologous immunoglobulin,
especially in very rare cases of IgA deficiency, when the
patient has antibodies against IgA.
Selection of doses for the trial
The study medication is being used within normal clin-
ical doses.
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Interventions will be available in 5 g/100 ml and 10 g/
200 ml bottles IntratectTM IVIg infusion or matching
placebo.
Each participant will be scheduled to receive infusions
of active IntratectTM (0.5 g/kg) or matching placebo day
1 post-randomisation and day 22 post-randomisation. In
exceptional circumstances, where a randomized patient
does not attend for the first infusion on day 1, delay of the
first infusion up to day 5 is acceptable. See in Additional
file 1: table of events.
Data collection timelines remain the same, regardless
of when infusions are received. Any patient who has not
received his/her trial infusion by day 5, that is, before
day 6, will be withdrawn and not given trial medication.
All patients receiving any amount of trial infusion on
days 1 to 5 will be included in the intention-to-treat ana-
lysis. All patients who receive ≥80% of the target dose
on day 1 will be included in the per-protocol analysis.
All patients will be offered open-label infusions of Intra-
tectTM on day 43 and day 64 post-randomization. Intra-
tectTM or placebo will be infused intravenously at an
initial rate of not more than 1.4 ml/kg/hr for 30 minutes.
If well tolerated, the rate of administration may be in-
creased to a maximum of 2.5 ml/kg/hr for the remainder
of the infusion. This is higher than the usual recom-
mended rate of 1.9 ml/kg/hr in order to ensure that the
entire infusion can be completed in a single day, and in
view of the experience of clinicians, higher rates of infu-
sion are generally well tolerated.
Infusion rate adjustments can be made if patients experi-
ence mild adverse clinical effects, reducing to 1.9 ml/kg/hr
in the first instance and further if required, while aimingTable 1 The dosing is based on the patient weight, clinicians
drug
Weight range Dose to be administered Kits (100 ml) to
be dispensed
35.5 to 45.4 kg 20 g -
45.5 to 55.4 kg 25 g 1
55.5 to 65.4 kg 30 g -
65.5 to 75.4 kg 35 g 1
75.5 to 85.4 kg 40 g -
85.5 to 95.4 kg 45 g 1
95.5 to 105.4 kg 50 g -
105.5 to 115.4 kg 55 g 1
115.5 to 125.4 kg 60 g -
125.5 to 135.4 kg 65 g 1
135.5 to 145.4 kg 70 g -
145.5 to 155.4 kg 75 g 1
155.5 to165.4 kg 80 g -for sufficient time to complete the entire infusion in a
single day.
Identity and supply of investigational medicinal product
IntratectTM IVIg infusion 10 g/200 ml - Biotest UK
IntratectTM IVIg infusion 5 g/100 ml - Biotest UK.
The trial medication is supplied as 100 ml and 200 ml
bottles containing 5 g and 10 g IVIg. The volume pre-
scribed per patient is weight determined (Table 1), with a
target of 0.5 g/kg.
Packaging and labelling of investigational medicinal
product
Investigational medicinal product will be supplied in in-
dividual 100 ml and 200 ml bottles, containing 5 g and
10 g IVIg, or 0.1% albumin in normal saline as a control.
For the day 1 and day 22 infusions, each bottle will be
blinded during dispensing by the study site pharmacy.
Day 43 and Day 64 infusions will use unblinded bottles
of IntratectTM 5 g/100 ml or 10 g/200 ml.
Packaging and labelling will be completed in accord-
ance with Good Manufacturing Practice (GMP) Annex
13 requirements and GCP, by the Aseptic Manufacturing
Pharmacy Unit (AMPU) at Royal Liverpool and Broadgreen
Hospital, Liverpool.
Label design for primary and secondary packaging
Label designs will incorporate a structure that allows the
IMP or placebo to remain blinded to clinical staff and
participants. Both the primary container (bottle) and the
secondary packing of the IMP and the placebo will be
labelled in an identical manner (Figure 1).should refer to this table before administering the study






2 400 ml 88 to 113 ml/hr
2 500 ml 113 to 138 ml/hr
3 600 ml 138 to 163 ml/hr
3 700 ml 163 to 188 ml/hr
4 800 ml 188 to 213 ml/hr
4 900 ml 213 to 238 ml/hr
5 1,000 ml 238 to 263 ml/hr
5 1,100 ml 263 to 288 ml/hr
6 1,200 ml 288 to 313 ml/hr
6 1,300 ml 313 to 338 ml/hr
7 1,400 ml 338 to 363 ml/hr
7 1,500 ml 363 to 388 ml/hr
8 1,600 ml 388 to 413 ml/hr
Figure 1 Example labels of the primary container (bottle) and
the secondary packing of the investigational medicinal product
(IMP) and the placebo.
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moved by the Pharmacy Departments at participating
sites at the point of blinding and dispensing.
The 6 tear-off sections of labels that will be detached
by the study site pharmacy department during dispens-
ing are described as follows:
1. INTRATECT 10 g/200 ml,
2. INTRATECT 5 g/100 ml,
3. PLACEBO 5 g/100 ml,
4. PLACEBO 10 g/200 ml,
5. OPEN LABEL INTRATECT 5 g/100 ml, or
6. OPEN LABEL INTRATECT 10 g/200 ml.
Prescription of investigational medicinal product
Study medication will be prescribed by an authorised
study physician according to the protocol, using a trial-
specific prescription. The volume to be dispensed per
patient will be calculated according to patient weight
(dosing-schedule Table 1) and the site pharmacist will
dispense the required number of bottles. Medication will
be dispensed according to local pharmacy practice. Bottles
will contain 100 ml or 200 ml of IVIg or placebo. Partici-
pants will be informed of potential adverse reactions and
advised to seek medical help and contact the research
team, if required. Patients will carry cards with an emer-
gency 24-hour code break number. Documentation of pre-
scribing, dispensing and return of study medication shall
be maintained for study records in the pharmacy file and
reconciled with the investigator site file at end of study. A
study-specific prescription must be submitted to phar-
macy the day prior to the patient’s infusion. The pharmacy
will have received an email from the randomisation service
at the time of randomisation, which must be printed and
filed with the dispensing records and which will be re-
ferred to by the dispensing pharmacist to decide whether
to dispense active or placebo medication for the blinded
infusions.
If the event that a 200-ml bottle is not available, it is per-
mitted to dispense two 100-ml bottles, but where possible
the preferred options are above. Where two 100-ml bottles
are dispensed, the trial manager must be informed as the
next shipment of drug to site may need to be adjusted as a
result. The exception is where the IMP expiry is coming
close and in the judgment of the site pharmacist, it makes
sense to use up some expiring 100-ml bottles in preference
to using 200-ml bottles with a later expiry. Ideally, this
should be discussed with the trial manager in advance.
Dispensing and distribution of investigational medicinal
product
The study drug will be stored in a secure area with lim-
ited access within each local pharmacy according to the
storage requirements documented on the clinical trial
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visit. A temperature log will be maintained as per local
pharmacy procedures.
Study medication will be distributed to the seven study
site pharmacies by and from the Aseptic Manufacturing
Pharmacy Unit (AMPU) at Royal Liverpool and Broad-
green Hospital, Liverpool. Study medication receipt will
be recorded in the study pharmacy file. A study medica-
tion dispensing and return log will be maintained by the
site pharmacies. Research staff will be instructed not to
dispose of empty medication bottles, but to return these
to pharmacy post-infusion.
Supplies of study medications dispensed on Day 1 and
Day 22 post-randomization will be blinded by the study
site pharmacy department by detaching the tear-off sec-
tion from both the primary container (bottle) and the
secondary packing. Dispensing records will be retained
by the study site pharmacy department. For those who
wish to receive open-label medication, either a single
additional open-label dose will be given on Day 43 post-
randomization, or additional open-label doses will be
given on both Day 43 and Day 64 post-randomization (if
patients wish to receive two open-label doses).
Administration of investigational medicinal product
If centres prefer to run a slower infusion than described
above, this will not be considered a protocol violation.
Patients may be offered paracetamol 1 g orally during
the infusion, where clinically indicated. Patients are
under continuous nurse observation during the infusion;
in cases where no reduction of the infusion rate is re-
quired, the infusion duration for a participant of 75 to
85 kg body weight is about 4.5 hours.
In the event that patients do not receive their entire
first infusion, either due to having to stop early because
of time constraints arising from long infusion duration
with a low rate, or because side effects are intolerable
even with the lowest infusion rate, they should still be
offered the second infusion, as patients often tolerate
second infusions better. Details of the amount infused
should be recorded in the medical notes and electronic
Case Report Form (eCRF).
Where the infusion cannot be tolerated and the pa-
tient wishes to not receive additional infusion, the pa-
tient is withdrawn from further infusion, but follow-up
data will be collected until the end of the study.
Concomitant medications
All concomitant drug therapies received will be recorded
at baseline and follow-up assessments.
Interactions include the following:
1) Live attenuated virus vaccines. Immunoglobulin ad-
ministration may impair for a period of at least 6 weeks
and up to 3 months the efficacy of live attenuated virusvaccines such as measles, rubella, mumps and varicella.
After administration of this product, an interval of
3 months should elapse before vaccination with live atten-
uated virus vaccines. In the case of measles, this impair-
ment may persist for up to 1 year. Therefore, patients
receiving measles vaccine should have their antibody sta-
tus checked.
2) Interference with serological testing. After injection
of immunoglobulin the transitory rise of the various
passively transferred antibodies in the patient’s blood
may result in misleading positive results in serological
testing. Passive transmission of antibodies to erythro-
cyte antigens, for example, A, B, and D, may interfere
with some serological tests including the antiglobulin
test (Coomb’s test).
Details of all other agents that might interact with Intra-
tectTM can be found in the British National Formulary
(BNF) (http://www.bnf.org/bnf/).
Study site investigators and patients will be provided
with an emergency 24-hr unblinding contact number.
Participants should not receive any other investigational
drugs or agents during their participation in the study.
Should patients experience a flare-up of their CRPS
pain or a trial intervention-induced reduction in pain
level, they may, in discussion with their PI (or a dele-
gated experienced pain specialist), increase or reduce the
dose of their current medications.
Safety monitoring
The following blood tests will be done at baseline only.
Additional blood monitoring is only required for the
protocol in response to adverse events.
Routine haematology
Routine haematology includes the following:
1. white blood cell and differential count (eosinophils,
basophils, neutrophils, lymphocytes and monocytes);












4. serum creatinine; and
5. ALT, AST, GGT, bilirubin.
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Pregnancy status will be verified using blood pregnancy
testing at baseline for female patients of childbearing po-
tential and urine pregnancy testing at visit 4 if patient is
receiving open-label IntratectTM.
Randomisation
Identification and randomisation of patients
A patient identification number will be allocated by reg-
istering the patient on the MACRO eCRF system after
consent has been signed. The system will generate a
unique identifier to be used throughout the study.
Patients will be allocated (on study day 0) to placebo
or IVIg (ratio 1:1) by sites via an online system based at
the King’s Clinical Trials Unit (King’s CTU), based at
the Institute of Psychiatry. Allocation will be at the level
of the individual patient via block randomisation with
randomly varying block sizes, stratified by centre.
Only site staff authorised to request randomisation will
receive passwords for the randomisation system. Re-
quests for passwords are via the trial manager of the
King’s CTU.
Implementation procedures
Sites will be responsible for maintaining a baseline of ‘in
date’ stock on shelf of both active and placebo IMPs.
Unblinded bottles for the open-label phase of the
study will also be available and supplied to participating
sites.
Once an eligible patient has provided written informed
consent and completed the baseline assessments, he/she
will be asked to complete pain diaries daily after the
screening visit until the infusion visit. The study site in-
vestigator will contact the patient by telephone at an
agreed time between 8 and 14 days after the screening
visit and collect screening pain diary scores. If the pa-
tient is eligible on pain diary and blood results, an infu-
sion visit will be scheduled.
Online randomisation will be requested by site one
day prior to the infusion. Patients can only be rando-
mised after the allocated study site nurse has confirmed
by telephone a) that the patient is well, b) that the pa-
tient is willing and able to come to the infusion unit the
next day, c) the details of the arranged transport, d) any
anticipated problems from the patient’s perspective, and
e) that the pharmacy will be able to dispense in good
time.
The randomisation system will automatically generate
two emails at the point of randomisation. The first will
be sent to appropriate members of the study team, who
are blinded to treatment allocation, and will just confirm
that the patient has been randomised. The second will
be sent to the dispensing pharmacy to inform them of
the treatment allocation and will be copied to the eSMSemergency code break service, so they have the unblinding
information available in the event of the need to unblind.
A study-specific prescription will be completed (for dosing
schedule, see Table 1) and sent to the pharmacy for dis-
pensing. The dispensing pharmacist will refer to the ran-
domisation email when the prescription is received. Any
bottle of IMP in the appropriate trial arm can be selected
for dispensing but if IMP is available with an earlier expiry
this should be used in preference to IMP with a later
expiry.Blinding
The trial will be double blinded. Blinding will be achieved
by preparing both study drug and placebo (0.1% albumin
in normal saline) solution into identical-looking bottles.
Batch numbers and expiry dates for both active and pla-
cebo drug will be indistinguishable.
The IMP will be supplied directly to designated phar-
macy contacts at participating sites. The tear-off section
on the primary container (bottle) and the secondary pack-
ing will inform the dispensing site pharmacy of the true
nature of contents (Active or Placebo). At dispensing, this
section of label is removed to maintain blinding.
In the event of an urgent need to unblind treatment,
the 24-hour emergency code break service must be con-
tacted This should be the preferred route to code break,
even in office hours when the site pharmacist is avail-
able, as there is then a full audit trail of the code break
event. The site pharmacy will also be aware of the pa-
tient’s treatment allocation.
Unblinding should only occur where knowledge of the
randomised treatment is needed for immediate patient
care and cannot be delayed until the next working day
when the study team can be contacted. Code breaks will
not be routinely opened for participants who complete
study treatment.
If a request for code break is received from a physician
(for example, the patient’s general practitioner) outside the
research team, Guy’s Medical Toxicology Unit (eSMS) will
attempt to contact the research team to verify the request
before the code is broken.
If the code is broken, details including patient study
number, the date code break was performed, the person
who broke the code, and the reason for the code break,
shall be recorded by the emergency code break service
and retained. The trial manager will be informed of the
unblinding event. If clinically indicated, the participant
will be withdrawn from the study medication.
Accidental unblindings will be dealt with on a case by
case basis if and when they arise. The patient’s data
should continue to be collected according to the visit
schedule, even in the event of unblinding or withdrawal
from study medication, unless the patient refuses.
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Trial database
An electronic Case Report Form (eCRF) will be created
using the InferMed Macro system. This system is regula-
tory compliant (GCP, 21CRF11, EC Clinical Trial Directive).
The eCRF will be created in collaboration with the trial
statisticians and the investigators and will be maintained by
the King’s Clinical Trials Unit. It will be hosted on a dedi-
cated secure server within KCL.
Source data will be entered by authorised staff onto
the eCRF with a full audit trail.
Database passwords, data handling and confidentiality/
format of records
Database access will be strictly restricted through pass-
words to the authorised research team.
Data will be handled, computerised and stored in ac-
cordance with the Data Protection Act, 1998. Participants
will be identified on the study database using a unique
code and initials. The investigator will maintain accurate
patient records/results detailing observations on each pa-
tient enrolled. All participant contact/screening and re-
cruitment data will be will be stored on spreadsheets
within the recruiting NHS sites, which will have restricted
access from password protected computers. Accrual data
uploaded to the UKCRN portfolio database will be anon-
ymised and collated by the Trial Manager to CLRN. No
identifiable data will be entered on the eCRF or trans-
ferred to the coordinating CTU.
At the end of the study, essential documentation will
be archived in accordance with sponsor and local re-
quirements. The retention of study data will be the
responsibility of the Chief Investigator.
On-site/central monitoring
The Trial Manager will conduct on-site/central monitor-
ing. The Data Manager/Statistician may identify data fields
that should be checked against the source data during site
monitoring visits, the specifics will be outlined in a Data
Management standard operating procedure (SOP). Where
there are data queries, the research nurses will be respon-
sible for resolving the queries. The Trial Manager will re-
view responses before closing the query.
Statistical considerations
Data analysis will be performed by the study statistician at
University College London, using a password-protected
computer in a private office.
Statistical analysis
A comprehensive statistical analysis plan will be developed
and agreed upon with the trial’s oversight committees. De-
scriptive analysis (for example, summary statistics andplots) will be performed to investigate the distribution of
the primary outcome, pain score, across participants.
Efficacy
Primary analysis The primary outcome will be analysed
using a mixed model to establish any difference between
pain scores after IVIg and placebo. The stratification factor
(centres) will be a fixed effect. The model will efficiently
model the repeated measurements data. Modelling as-
sumptions will be checked (for example, residuals). All
analyses will be performed on an intention-to-treat basis.
Every effort will be made to reduce loss to follow-up
(using phone calls etcetera). Participants who do not con-
tribute any outcome measurements for the primary out-
come will be omitted from the analysis. Participants who
provide any outcome data will be included. No imputation
will be performed.
Secondary analysis As a secondary analysis, we will cal-
culate the proportion of patients in each arm who
achieve 50% or 30% pain relief (based on the average
pain level entered on day 6 to 42), compared to their
baseline level of pain (the average pain level recorded
during the first 7 days of the screening period). Using
these proportions, we will calculate the number needed
to treat (NNT) with IVIg, so that one additional patient
will achieve 50% pain relief.
Possible changes in treatment effect over time and asso-
ciation between disease duration, psychological baseline
measurements, allergy status, low baseline IgG plasma
level, IgG increase, and treatment response, as well as any
association between psychological measurements with the
primary outcome, will be investigated using exploratory
plots and regression models with interaction terms.
Change in the McGill Pain Questionnaire (Short Form)
descriptor terms [25] limb temperature and QST changes
before-after IVIg/placebo treatments on affected/contra
lateral sides, pain interference and quality of life (QoL)
outcomes will be investigated using either standard re-
gression models or mixed models. In those who decide
to receive both open infusions, and who have at least
30% or 2 NRS points average pain relief from 6 to
20 days after their last open infusion as compared with
baseline, the time between the last open infusion and
the first period with average weekly pain equalling or
exceeding baseline -1NRS point) is calculated as the
IVIg effect duration. As the study ends on day 148
(12 weeks after the second open infusion), later effects
will not be recorded.
Safety
An interim analysis will be performed for futility and
safety after half of patients have completed the trial. The
trial may be stopped if there is a statistically significant
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test), and if with the statistician remaining blinded, the
unblinded DMC recognizes that the effect is in the
‘wrong’ direction. This stopping rule will only have a
minor effect on the type I error and power of the trial.
There will no statistical stopping rule for efficacy al-
though the data monitoring committee (DMC) may sug-
gest stopping the trial on the grounds of safety if there is
an overwhelming positive effect of IVIg.
All causes of withdrawal from randomised treatment
will be reported at days 22 and 43 post- randomisation.
The prevalence of adverse events and reactions will be re-
ported descriptively at 22 and 43 days post-randomisation.
For patients an open-label infusion, AE’s reported from 43
to 85 days post-randomisation will be tabulated separately
for reports rather than being reported with blinded AE’s.
Sample size calculation
The sample size was calculated as follows: 122 partici-
pants are required to detect a difference in pain score of
1.2 using a two-sample t-test assuming 5% statistical sig-
nificance, 85% power and a common standard deviation
of 2.2 (as in our previous study (8)). Assuming 10% loss
to follow-up and 5% noncompliance increases, this num-
ber increases to 152 participants. We actually intend to
collect 37 measurements of pain intensity (the primary
outcome) per participant and analyse the outcome using
a mixed-effects regression model.
Thus we can reduce this sample size based on these
extra measurements. The correlation among a patient’s
measures is assumed to be 0.7 (from our previous study),
and hence, the multiplying factor is as follows:
1þ 37−1ð Þ  0:7ð Þ=37 ¼ 0:71




Compliance will be measured by attendance at infusion
visits on day 1 and day 22 and tolerance of entire pre-
scribed infusion.
Treatment cessation
Patients who develop an unexpected new condition pre-
cluding further participation will be withdrawn from re-
ceiving further infusions, but will continue to complete
daily pain diaries and asked to attend for collection of
other outcome data (intention to treat). If patients do
not tolerate blinded infusion 1, they may still be admin-
istered blinded infusion 2 if both the patient and clin-
ician are agreeable.Withdrawal of participants
Study drug must be discontinued for the following:
1. the participant decides he/she no longer wishes to
continue;
2. withdrawal is recommended by the Investigator or
another clinician (for example, intercurrent illness
during course of study or side effects from study
drug); or
3. the trial is terminated at the request of the DMC.
Patients will be discontinued for the following:
1. they are randomized, but never receive any drug
(that is, the first infusion is never started - this is
also termed ‘non-compliance’) or
2. they do not provide any values for the day 6 to 43
outcome pain diary data (this is also termed ‘missing
data’).
Participants have the right to withdraw from the study
at any time and for any reason without providing a rea-
son. The investigator also has the right to withdraw par-
ticipants from the study if they consider that it is in the
best interests of the participant. Should a participant de-
cide to withdraw from the study, he/she will be asked to
volunteer a reason for withdrawal but are at liberty not
to state a reason.
Should a participant withdraw from study drug only,
efforts will be made to continue to obtain follow-up data
with the permission of the patient. Subjects who with-
draw from treatment early will be encouraged to return
to the study site for follow-up until day 43, providing
that consent is not withdrawn.Data monitoring, quality control and quality assurance
Discontinuation rules
The trial may be prematurely discontinued on the basis of
predefined stopping criteria, or for other reasons given by
the independent Data Monitoring and Ethics Committee,
study sponsor, regulatory authority or ethics committee
concerned.Monitoring, quality control and assurance
The LIPS protocol has been developed with extensive re-
view by clinicians, statisticians, and patient groups.
The LIPS Trial Coordination Centre will be based in the
King’s Clinical Trials Unit in the Department of Biostatistics
at the Institute of Psychiatry, King’s College London (IoP/
KCL). Day to day management of LIPS will be the responsi-
bility of the Chief Investigator and the Trial Manager. The
Coordinating Centre will arrange meetings of the Trial
Management Group (TMG) and Trial Steering Committee
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Committee (DMC) meetings.
The TMG will comprise Dr Andreas Goebel (Chair), the
Trial Manager, the Data Manager, the Trial Statistician, and
the manager of King’s Clinical Trials Unit. The TMG will
arrange telephone conferences and provide monthly re-
cruitment email updates during recruitment and status re-
ports, and 6 monthly thereafter. The TMG will organise a
meeting for all PIs (and for key staff working on the study)
to sign the protocol, and to agree on the content and
undergo training on SOPs before the start of recruitment.
A second investigators’ meeting will be held at the end of
the study to review the results. The TMG will also meet
face-to-face every 6 months in Liverpool or London. The
TMG will report to the Trial Steering Committee (TSC).
All PIs will be kept informed of TSC and DMC advice and
consulted by e-mail or teleconference as required.
The TSC will consist of an independent chair, two inde-
pendent members, a site investigator, a patient representa-
tive, a nonvoting member, and the Chief Investigator; the
names are detailed on page 4 of this protocol. The TSC
will be responsible for approving the trial protocol and
overseeing the conduct of the study, including advising on
continuing or stopping the study in the light of advice
from the DMEC. Meetings of the TSC will be held at least
annually.
Membership of the DMEC will comprise an Independ-
ent Chair; an independent specialist with interest in
neuropathic pain analgesic trials, and an independent
statistician. The DMC will have access to the unblinded
data and will monitor the progress of the trial in terms
of safety and ethical issues. The DMC may advise the
TSC to continue or to stop the trial according to pre-
agreed upon stopping rules.
The Principal Investigators will be responsible for the
day-to-day study conduct at site. This includes establishing
and carrying out the trial at his/her centre in accordance
with international, national and local law and regulations
and GCP. They will ensure that all site specific documen-
tation is complete and correct; and that all staff involved
in the trial are compliant with Trust, GMC and other rele-
vant regulations, and that they are appropriately trained in
those aspects of GCP relevant to their role in the study
whilst being familiar with the trial protocol.Principle In-
vestigators are also responsible for managing recruitment
on target and collecting and submitting accrual and out-
come data in a timely manner; responding in timely fash-
ion to requests from the Trial Coordinating Centre for
information; providing and responding promptly to SAE
and suspected unexpected serious adverse reaction (SUS-
ARs) reports; agreeing to monitoring and audit visits as
required.
Central and site monitoring of study conduct and data
collected will be performed by the Trial Manager at theKCTU on behalf of the Sponsor. Full details will be doc-
umented in a monitoring plan, agreed upon with the
study sponsor. The main areas of focus will include con-
sent, serious adverse events, essential documents, and
drug accountability and management. All monitoring
findings will be reported and followed up with appropri-
ate persons in a timely manner.
The study may also be subject to audit or inspection
by the University of Liverpool or the Walton NHS Trust
under their remit as co-sponsors, or by MHRA or other
regulatory bodies to ensure adherence to GCP and regu-
latory requirements.
Direct access to source data and documents
The investigators agree to provide full access to all source
data, study data and materials to the trust research gov-
ernance department, ethics committee, regulatory author-




Adverse event reporting will be in compliance with GCP.
Most adverse drug reactions that occur in this study,
whether serious or not, will be expected treatment-related
side effects as IVIg has a well-established side-effect profile.
IntratectTM can cause adverse reactions such as chills,
headache, fever, vomiting, allergic reactions, nausea, arth-
ralgia, low blood pressure and mild back pain, which may
occur occasionally.
Rarely, human normal immunoglobulins may cause a
sudden fall in blood pressure, and in isolated cases, ana-
phylactic shock, even when the patient has shown no
hypersensitivity to previous administration.
Cases of reversible aseptic meningitis, isolated cases of
reversible haemolytic anaemia/haemolysis, and rare cases
of transient cutaneous reactions have been observed with
human normal immunoglobulin.
Increase in serum creatinine level and/or acute renal
failure have been observed.
Very rarely, thromboembolic reactions, such as myo-
cardial infarction, stroke, pulmonary embolism, and deep
vein thromboses have occurred.
Details of further spontaneously reported adverse reac-
tions include the following:
1. cardiac disorders: angina pectoris (very rare);
2. general disorders and administrations site
conditions: rigors (very rare);
3. immune system disorders: anaphylactoid shock (very
rare), hypersensitivity (very rare);
4. investigations: blood pressure decreased (very rare);
5. musculoskeletal and connective tissue disorders:
back pain (very rare);
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dyspnoea NOS (very rare); or
7. vascular disorders: shock (very rare).
The adverse events reported above are expected in the
sense that they are possible known side-effects of the
study medication, but all reported instances of both ser-
ious and non-serious adverse events will be reported in
this study.
During the trial, investigators will be made aware of
any updates to the summary of product characteristics
(SPC) but the protocol need not be amended every time
there is a change unless it directly affects the study con-
duct. The source of accurate information regarding the
active medication must always be the SPC and not the
study protocol, and the above information is provided to
reflect the situation at study start only.
Protocol specifications
For purposes of this protocol
1. Any serious adverse events will be recorded
throughout the duration of the trial until 21 days
after cessation of study drug or until resolution.
2. Non-serious adverse events will be recorded
throughout duration of trial until 21 days after
cessation of study drug.
3. Serious adverse events exclude any pre-planned
hospitalisations not associated with clinical
deterioration.
Recording and reporting serious adverse events or
reactions
All adverse events and all serious adverse events should be
recorded. Depending on the nature of the event, the
reporting procedures below should be followed. Any ques-
tions concerning adverse event recording/reporting should
be directed to the Trial Manager in the first instance.
Non-serious adverse events
All non-serious adverse events will be recorded on the
study CRF. Severity of all AEs will be graded on a three-
point scale of intensity (mild, moderate, or severe):
Mild: Discomfort is noticed, but there is no disruption
of normal daily activities.
Moderate: Discomfort is sufficient to reduce or affect
normal daily activities.
Severe: Discomfort is incapacitating, with inability to
work or to perform normal daily activities.
Relation of an AE to treatment should be assessed by
the investigator/delegate (must be a clinician) on-site.
Investigators will be responsible for managing all adverse
events according to local protocols, as the study drug is
already licensed for use in other indications.Serious Adverse Event/Reaction (SAE/SAR, including SUSARs)
All SAEs, SARs and SUSARs shall be recorded and re-
ported on the serious adverse event form to the Chief
Investigator/delegate within 24 hours of learning of its
occurrence. The initial report can be made by complet-
ing the serious adverse event form, and faxing or email-
ing into the King’s CTU. A record of this notification
(including date of notification) must be clearly docu-
mented to provide an audit trail. In the case of incom-
plete information at the time of initial reporting, all
appropriate information should be provided as follow-up
as soon as this becomes available.
Relationship of the SAE to the treatment should be
assessed by the investigator/delegate (must be a clin-
ician) at that site, as should the expected or unexpected
nature of any serious adverse reactions. As this is a
blinded trial involving a placebo and active drug, ser-
iousness, causality and expectedness should be evaluated
as though the patient was on the active drug.
All SUSAR-reporting responsibilities to MHRA will be
that of the Sponsor, with the support of the Kings CTU.
The Sponsor will report SUSARs (Suspected Unexpected
Serious Adverse Reactions) and other SARs to the
regulatory authority (MHRA).
The Chief Investigator will report to the relevant
ethics committees, with the support of the Kings CTU.
Reporting timelines are as follow:
SUSARs that are fatal or life-threatening must be
reported no later than 7 days after the sponsor is first
aware of the reaction. Any additional relevant information
must be reported within a further 8 days.
SUSARs that are not fatal or life-threatening must be
reported within 15 days of the sponsor first becoming
aware of the reaction.
The Chief Investigator will provide an annual report of
all SARs (expected and unexpected), and SAEs which
will be distributed to the Sponsor, MHRA and the REC.
As this is a blinded study, cases that are considered
SUSARs would have to be unblinded to the King’s
CTU manager prior to reporting to the Sponsor and
main REC. Only those events occurring among patients
on the active drug (unless thought to be due to the
excipient in the placebo) should be considered
SUSARs.
All investigators will be informed of all SAE’s assessed
as fulfilling criteria as a SUSAR (that is, possibly,
probably or definitely related to the study intervention
and unexpected per the SPC) on a case-by-case basis.
This will be regardless of medication administered in
order to avoid the risk of inadvertently unblinding
investigators, unless this information is needed for
medical management of patients. Therefore, occasions
may arise where a potential SUSAR is unblinded and if
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need to be informed, and the investigators will not be
made aware of this information. All reports to PIs will
refer to events fulfilling criteria as a ‘potential SUSAR’
and only the KCTU and Sponsor will be aware of the
events reported onward to the MHRA in an expedited
manner.
The Chief Investigator will ensure University of
Liverpool as lead sponsor is notified of any potential
SUSARs.
*The Trial coordinating centre MUST be informed of
all SAEs or SUSARs within 24 hours of learning of its
occurrence. A record of this notification (including
date of notification and acknowledgement of receipt
from the KCTU) must be clearly documented to
provide an audit trail.
The KCTU will onward report to the CI and Sponsor
in compliance with regulatory requirements.Pregnancy
Should a trial participant become pregnant during the
trial, she will be immediately withdrawn from study
treatment, and the pregnancy will be followed up until
outcome. The need to unblind will be considered on a
case-by-case basis. Pregnancy will be reported as a ser-
ious adverse event. Data collection at the planned sched-
uled follow-up timeline must continue, unless the
patient is unwilling to provide further data.Research blood samples
Research blood samples will be requested at baseline
and day 43. Patients not consenting to provide research
blood samples may still be randomised into the study.
Patients only willing to provide research blood samples
on a single occasion will just have the first sample taken.
On consenting patients, 30 ml of blood will be col-
lected in a gel tube and centrifuged at 2,000 G for 10 mi-
nutes according to local policy (no specific centrifuge
protocol is required). Serum must then be pipetted or
poured into 10-ml aliquots and stored frozen in a -20 or
-80 freezer. Each aliquot must be labelled with the pa-
tients study PIN, initials, date of birth and date of sam-
ple collection. Details of sample collection must be
entered on the eCRF system.
The blood samples will be used to examine serum
antibodies, mediators or substances in patients with
complex regional pain syndrome. Samples will be stored
and examined for 30 years.
On a periodic basis, the study monitor will arrange for a
shipment of dry ice to be delivered to the study site and
for samples to be shipped via courier to the University of
Liverpool on the same day. Shipment forms will be pro-
vided to sites by the study monitor.Ethics and regulatory issues
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical As-
sembly, Helsinki 1964 and later revisions.
Information sheets will be provided to all eligible sub-
jects and written informed consent obtained prior to any
study procedures. Participants will be provided with a
copy of the completed consent form for their records.
Favourable ethical opinion and MHRA Clinical Trial
Authorisation has been obtained along with local ap-
provals including site specific assessment and trust re-
search and development approval. The participating sites
have also signed a Clinical Trial Agreement (CTAg) with
the study sponsor. The Trial Coordination Centre at the
King’s Clinical Trials Unit required a written copy of
local approval documentation and a copy of the signed
CTAg before initiating each centre and accepting partici-
pants into the study.
Approval has been granted from the NRES Committee
East of England - Hatfield.
The REC Reference Number is 12/EE/0164.
A detailed table showing all substantial amendments
and what was changed is detailed in Additional file 5.
Local research and development approval has been
granted from all infusion sites: Liverpool (The Walton
Centre NHS Foundation Trust), Bath (Royal National
Hospital for Rheumatic Disease NHS Foundation trust),
Cambridge (Cambridge University Hospitals Foundation
Trust at Addenbrookes), Glasgow (Greater Glasgow and
Clyde Trust at Gartnavel), London (Guys and St Thomas’
NHS Foundation Trust), Norwich (Norfolk and Norwich
University NHS Foundation Trust) and Leicester (Univer-
sity Hospitals of Leicester NHS Foundation Trust).
Finance and insurance
NIHR EME is the main funder of this study. Biotest UK
Ltd will provide active study medication free of charge
and some funds. The Pain Relief Foundation, Liverpool,
has provided additional support funding to the study.
The participating NHS Trusts have liability for clinical
negligence that harms individuals towards whom they
have a duty of care. NHS indemnity covers NHS staff
and medical academic staff with honorary contracts
conducting the trial. University insurance covers re-
search staff who have their substantive contracts with
the University for Potential Liability for issues arising
from negligence in study design. There are no arrange-
ments for non-negligent compensation.
Publication policy
The data will be the property of the co-sponsors. Publi-
cation will be the responsibility of the Chief Investigator.
Results from the study will be submitted for publication
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nals. All manuscripts, abstracts or other modes of pres-
entation will be reviewed by the TSC and DMC prior to
submission. No reference will be made to any particular
study subject. Results of the study will also be reported
to the Sponsor and Funder in the required format.
Participants will be informed about their treatment al-
location at the end of the study, along with a summary
of the results, once the primary paper has been accepted
for publication.
Discussion
This protocol will allow us to determine if low dose intra-
venous immunoglobulin is an effective treatment for com-
plex regional pain syndrome. We hope to have all 108
patients recruited by 30 November 2015 with write-up be-
ing completed by 31 July 2016.
Trial status
Current Status: Open
Closure Date: 30 November 2015
Global Sample Size: 108
Additional files
Additional file 1: Table of events - summary of study procedures.
It provides a comprehensive overview of the study procedures, the visit
dates are shown along the top column, the left side column shows
procedures and the crosses in the table indicate which visit they should
be done on. Scheduled telephone calls are also shown on this table.
Additional file 2: Research Diagnostic Criteria (the “Budapest
Criteria”) for Complex Regional Pain Syndrome. It shows the research
diagnostic criteria (Budapest) for Complex Regional Pain Syndrome, this is
the criteria that patient’s illness must meet to be enrolled into the trial.
Additional file 3: Recruitment Strategy. A table that summarises the
various recruitment strategies utilised in this study given information on
where, who would approach and how they then enrol.
Additional file 4: Intratect Summary of Product Characteristics.
A web link to a page that provides full details of the infusion drug.
Additional file 5: Summary of substantial amendments. A table that
details each substantial amendment that has been submitted for this
protocol and what exactly was changed during that amendment.
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